• Je něco špatně v tomto záznamu ?

Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA] trial)

H. Eltchaninoff, N. Bonaros, B. Prendergast, F. Nietlispach, M. Vasa-Nicotera, A. Chieffo, P. Pibarot, P. Bramlage, L. Sykorova, J. Kurucova, JJ. Bax, S. Windecker, N. Dumonteil, D. Tchetche,

. 2020 ; 228 (-) : 27-35. [pub] 20200630

Jazyk angličtina Země Spojené státy americké

Typ dokumentu protokol klinické studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027749
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 32745733
DOI 10.1016/j.ahj.2020.06.016
Knihovny.cz E-zdroje

BACKGROUND: Limited data suggest that transcatheter (TAVR) as compared with surgical aortic valve replacement (SAVR) may be more effective in female than male patients. To date, most evidence is derived from subgroup analyses of large trials, and a dedicated randomized trial evaluating whether there is a difference in outcomes between these interventions in women is warranted. The RHEIA trial will compare the safety and efficacy of TAVR with SAVR in women with severe symptomatic aortic stenosis requiring aortic valve intervention, irrespective of surgical risk. METHODS/DESIGN: The RHEIA trial is a prospective, randomized, controlled study that will enroll up to 440 patients across 35 sites in Europe. Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status, will be randomized 1:1 to undergo aortic valve intervention with either transfemoral TAVR with the SAPIEN 3 or SAPIEN 3 Ultra device or SAVR and followed up for 1 year. The objective is to determine whether TAVR is non-inferior to SAVR in this patient population and, if this is fulfilled whether TAVR is actually superior to SAVR. The primary safety/efficacy endpoint is a composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure) at 1 year post-procedure. Other outcomes (assessed at 30 days and/or 1 year) include all-cause mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular function; cognitive function, health status, and quality of life. DISCUSSION: The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk. The results will be the first to provide specific randomized evidence to guide treatment selection in female patients with severe symptomatic aortic stenosis. TRIAL REGISTRATION: clinicaltrials.gov: NCT04160130.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027749
003      
CZ-PrNML
005      
20210303141944.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ahj.2020.06.016 $2 doi
035    __
$a (PubMed)32745733
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Eltchaninoff, Helene $u Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, Rouen, France. Electronic address: helene.eltchaninoff@chu-rouen.fr.
245    10
$a Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA] trial) / $c H. Eltchaninoff, N. Bonaros, B. Prendergast, F. Nietlispach, M. Vasa-Nicotera, A. Chieffo, P. Pibarot, P. Bramlage, L. Sykorova, J. Kurucova, JJ. Bax, S. Windecker, N. Dumonteil, D. Tchetche,
520    9_
$a BACKGROUND: Limited data suggest that transcatheter (TAVR) as compared with surgical aortic valve replacement (SAVR) may be more effective in female than male patients. To date, most evidence is derived from subgroup analyses of large trials, and a dedicated randomized trial evaluating whether there is a difference in outcomes between these interventions in women is warranted. The RHEIA trial will compare the safety and efficacy of TAVR with SAVR in women with severe symptomatic aortic stenosis requiring aortic valve intervention, irrespective of surgical risk. METHODS/DESIGN: The RHEIA trial is a prospective, randomized, controlled study that will enroll up to 440 patients across 35 sites in Europe. Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status, will be randomized 1:1 to undergo aortic valve intervention with either transfemoral TAVR with the SAPIEN 3 or SAPIEN 3 Ultra device or SAVR and followed up for 1 year. The objective is to determine whether TAVR is non-inferior to SAVR in this patient population and, if this is fulfilled whether TAVR is actually superior to SAVR. The primary safety/efficacy endpoint is a composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure) at 1 year post-procedure. Other outcomes (assessed at 30 days and/or 1 year) include all-cause mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular function; cognitive function, health status, and quality of life. DISCUSSION: The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk. The results will be the first to provide specific randomized evidence to guide treatment selection in female patients with severe symptomatic aortic stenosis. TRIAL REGISTRATION: clinicaltrials.gov: NCT04160130.
650    _2
$a senioři $7 D000368
650    12
$a aortální chlopeň $x diagnostické zobrazování $x chirurgie $7 D001021
650    12
$a aortální stenóza $x diagnóza $x patofyziologie $x psychologie $x chirurgie $7 D001024
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdravotní stav $7 D006304
650    12
$a srdeční chlopně umělé $x škodlivé účinky $x klasifikace $7 D006350
650    _2
$a lidé $7 D006801
650    _2
$a výsledky a postupy - zhodnocení (zdravotní péče) $7 D010043
650    12
$a pooperační komplikace $x diagnóza $x patofyziologie $x prevence a kontrola $x psychologie $7 D011183
650    12
$a kvalita života $7 D011788
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a zohlednění rizika $x metody $7 D020379
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $x přístrojové vybavení $x metody $7 D065467
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bonaros, Nikolaos $u Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: nikolaos.bonaros@tirol-kliniken.at.
700    1_
$a Prendergast, Bernard $u St. Thomas' Hospital, London, United Kingdom. Electronic address: bernard.prendergast@gstt.nhs.uk.
700    1_
$a Nietlispach, Fabian $u CardioVascularCenter, Hirslanden Klinik Im Park, Zurich, Switzerland. Electronic address: fabian.nietlispach@hirslanden.ch.
700    1_
$a Vasa-Nicotera, Mariuca $u University Heart Center Frankfurt, Frankfurt, Germany. Electronic address: mariuca.vasa-nicotera@kgu.de.
700    1_
$a Chieffo, Alaide $u Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: chieffo.alaide@hsr.it.
700    1_
$a Pibarot, Philippe $u Department of Cardiology, Quebec Heart & Lung Institute, Laval University, Quebec City, QC, Canada. Electronic address: philippe.pibarot@med.ulaval.ca.
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. Electronic address: peter.bramlage@ippmed.de.
700    1_
$a Sykorova, Lenka $u Edwards Lifesciences, Prague, Czech Republic. Electronic address: lenka_sykorova@edwards.com.
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic. Electronic address: jana_kurucova@edwards.com.
700    1_
$a Bax, Jeroen Joost, $u Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: j.j.bax@lumc.nl. $d 1966- $7 xx0257767
700    1_
$a Windecker, Stephan $u Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address: Stephan.Windecker@insel.ch.
700    1_
$a Dumonteil, Nicolas $u Groupe Cardiovasculaire Interventionnel, Clinique Pasteur Toulouse, France. Electronic address: ndumonteil@clinique-pasteur.com.
700    1_
$a Tchetche, Didier $u Groupe Cardiovasculaire Interventionnel, Clinique Pasteur Toulouse, France. Electronic address: dtchetche@clinique-pasteur.com.
773    0_
$w MED00000228 $t American heart journal $x 1097-6744 $g Roč. 228, č. - (2020), s. 27-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32745733 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210303141857 $b ABA008
999    __
$a ok $b bmc $g 1608084 $s 1118929
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 228 $c - $d 27-35 $e 20200630 $i 1097-6744 $m The American heart journal $n Am Heart J $x MED00000228
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace